Source comparison
MK-677 for Post-Workout Recovery: Product Comparison
MK-677 (Ibutamoren) Ghrelin receptor agonist (GHS-R1a) 25mg daily 4–6 hours 24–48 hours post-dose Oral Preserves pulsatile GH secretion pattern; oral bioavailability eliminates injection requirement GHRP-2 Growth hormone secretagogue receptor agonist 100–300mc
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (GHS-R1a)
- 25mg daily
- 4–6 hours
- 24–48 hours post-dose
- Oral
- Preserves pulsatile GH secretion pattern; oral bioavailability eliminates injection requirement
- GHRP-2
- Growth hormone secretagogue receptor agonist
- 100–300mcg per dose, 2–3x daily
- 20–30 minutes
- 3–6 hours per pulse
- Subcutaneous injection
- Shorter half-life allows precise timing relative to training; less appetite stimulation
- CJC-1295 (DAC)
- GHRH analog with extended half-life
- 2mg weekly
- 6–8 days
- Sustained elevation for 7–10 days
- Longer duration reduces dosing frequency; synergistic when combined with GHRP compounds
- Exogenous GH
- Direct growth hormone replacement
- 2–4 IU daily (research context)
- 2–3 hours
- 12–24 hours (dose-dependent)
- Highest magnitude IGF-1 response; bypasses endogenous secretion entirely; regulatory constraints limit accessibility
- Professional Assessment
- MK-677 offers the most practical balance for post-workout recovery research: oral administration, sustained IGF-1 elevation, and preserved physiological pulsatility without the injection burden of peptide secretagogues or the regulatory complexity of direct GH. The appetite stimulation is manageable with evening dosing.